Late-onset frontotemporal dementia associated with progressive supranuclear palsy/argyrophilic grain disease/Alzheimer’s disease pathology

Progressive supranuclear palsy (PSP) is typically manifested by vertical supranuclear gaze palsy, frequent falls early in the disease course, axial rigidity and poor response to levodopa. Prominent anterograde memory dysfunction with subsequent impairment in other cognitive domains is characteristic of Alzheimer’s disease (AD). No clear clinical syndrome has been identified in argyrophilic grain disease (AGD). Frontotemporal dementia (FTD) is characterized by apathy, emotional blunting, disinhibition, and impairment in executive functioning despite relatively preserved memory and visuospatial abilities. Cognitive deficits are known to occur in PSP; however, overt clinical FTD without parkinsonism or supranuclear gaze palsy associated with PSP pathology has rarely been documented. We report an elderly patient with the typical clinical, neuropsychometric, and neuroimaging features of FTD who had autopsy findings most consistent with PSP plus AGD and AD in limbic structures. We suggest that PSP with or without coexisting AD and AGD be included in the differential diagnosis of patients presenting with FTD.

[1]  M. Sjögren,et al.  The prevalence of frontal variant frontotemporal dementia and the frontal lobe syndrome in a population based sample of 85 year olds , 2003, Journal of neurology, neurosurgery, and psychiatry.

[2]  R. Petersen,et al.  Progressive Nonfluent Aphasia and Subsequent Aphasic Dementia Associated with Atypical Progressive Supranuclear Palsy Pathology , 2003, European Neurology.

[3]  P. Lantos,et al.  Office of Rare Diseases Neuropathologic Criteria for Corticobasal Degeneration , 2002, Journal of neuropathology and experimental neurology.

[4]  Dennis W. Dickson,et al.  Ballooned neurons in progressive supranuclear palsy are usually due to concurrent argyrophilic grain disease , 2002, Acta Neuropathologica.

[5]  J. Currie,et al.  Frontal atrophy correlates with behavioural changes in progressive supranuclear palsy. , 2002, Brain : a journal of neurology.

[6]  T. Iwatsubo,et al.  Late‐onset frontotemporal dementia with a novel exon 1 (Arg5His) tau gene mutation , 2002, Annals of neurology.

[7]  B Miller,et al.  Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. , 2001, Archives of neurology.

[8]  M. Rossor Pick’s disease: A clinical overview , 2001, Neurology.

[9]  E. Bigio,et al.  Cortical Synapse Loss in Progressive Supranuclear Palsy , 2001, Journal of neuropathology and experimental neurology.

[10]  E. Tolosa,et al.  Familial atypical progressive supranuclear palsy associated with homozigosity for the delN296 mutation in the tau gene , 2001, Annals of neurology.

[11]  M. Hutton,et al.  Phenotypic correlations in FTDP-17 , 2001, Neurobiology of Aging.

[12]  E. Kaplan,et al.  The Boston naming test , 2001 .

[13]  Hidenao Fukuyama,et al.  Comparison of the pattern of atrophy of the corpus callosum in frontotemporal dementia, progressive supranuclear palsy, and Alzheimer's disease , 2000, Journal of neurology, neurosurgery, and psychiatry.

[14]  C. Cotman,et al.  Clinical and pathological evidence for a frontal variant of Alzheimer disease. , 1999, Archives of neurology.

[15]  R. Faber,et al.  Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. , 1999, Neurology.

[16]  D. F. Brown,et al.  Progressive supranuclear palsy with dementia: cortical pathology. , 1999, Journal of neuropathology and experimental neurology.

[17]  E. Tangalos,et al.  Normative data for the Mattis Dementia Rating Scale. , 1998, Journal of clinical and experimental neuropsychology.

[18]  Ronald C. Petersen,et al.  Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17 , 1998, Nature.

[19]  C. Jack,et al.  Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease , 1997, Neurology.

[20]  D. Maraganore,et al.  2-30-01 Clinicopathologic heterogeneity in clinically- and/or pathologically-diagnosed cortical-basal ganglionic degeneration , 1997, Journal of the Neurological Sciences.

[21]  A. Lang,et al.  Cortical degeneration in progressive supranuclear palsy. A comparison with cortical-basal ganglionic degeneration. , 1997, Journal of neuropathology and experimental neurology.

[22]  D. Dickson,et al.  Neurodegenerative disorders with extensive tau pathology: A comparative study and review , 1996, Annals of neurology.

[23]  I Litvan,et al.  Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[24]  J. Hodges,et al.  Progressive supranuclear palsy presenting with dynamic aphasia. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[25]  M. Adams,et al.  Complete analysis of the presenilin 1 gene in early onset Alzheimer's disease , 1996, Neuroreport.

[26]  D. Dickson,et al.  Neuropathologic Overlap of Progressive Supranuclear Palsy, Pick's Disease and Corticobasal Degeneration , 1996, Journal of neuropathology and experimental neurology.

[27]  Y. Agid,et al.  Are explicit memory disorders of progressive supranuclear palsy related to damage to striatofrontal circuits? Comparison with Alzheimer's, Parkinson's, and Huntington's diseases , 1994, Neurology.

[28]  E G Tangalos,et al.  Memory function in very early Alzheimer's disease , 1994, Neurology.

[29]  D. Schaid,et al.  Apolipoprotein E: risk factor for Alzheimer disease. , 1994, American journal of human genetics.

[30]  P N Leigh,et al.  Cognitive deficits in progressive supranuclear palsy, Parkinson's disease, and multiple system atrophy in tests sensitive to frontal lobe dysfunction. , 1994, Journal of neurology, neurosurgery, and psychiatry.

[31]  F J Dunne,et al.  Subcortical dementia. , 1993, BMJ.

[32]  E. Tangalos,et al.  The short test of mental status. Correlations with standardized psychometric testing. , 1991, Archives of neurology.

[33]  Y Agid,et al.  Positron emission tomography study in progressive supranuclear palsy. Brain hypometabolic pattern and clinicometabolic correlations. , 1990, Archives of neurology.

[34]  J. Grafman,et al.  Frontal lobe function in progressive supranuclear palsy. , 1990, Archives of neurology.

[35]  A. Bol,et al.  Positron tomography demonstrates frontal lobe hypometabolism in progressive supranuclear palsy , 1989, Annals of neurology.

[36]  F Lhermitte,et al.  Slowing of cognitive processing in progressive supranuclear palsy. A comparison with Parkinson's disease. , 1988, Archives of neurology.

[37]  K P Offord,et al.  A short test of mental status: description and preliminary results. , 1987, Mayo Clinic proceedings.

[38]  A. Lees,et al.  Cognitive deficits in the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). , 1985, Journal of neurology, neurosurgery, and psychiatry.

[39]  S. Kish,et al.  Progressive supranuclear palsy: Relationship between extrapyramidal disturbances, dementia, and brain neurotransmitter markers , 1985, Annals of neurology.

[40]  M. Albert,et al.  The `subcortical dementia' of progressive supranuclear palsy , 1974, Journal of neurology, neurosurgery, and psychiatry.

[41]  J. Olszewski,et al.  Progressive Supranuclear Palsy: A Heterogeneous Degeneration Involving the Brain Stem, Basal Ganglia and Cerebellum With Vertical Gaze and Pseudobulbar Palsy, Nuchal Dystonia and Dementia , 1964 .

[42]  P. Rubé,et al.  L’examen Clinique en Psychologie , 1959 .

[43]  R. Reitan Validity of the Trail Making Test as an Indicator of Organic Brain Damage , 1958 .

[44]  L. Bender A VISUAL MOTOR GESTALT TEST AND ITS CLINICAL USE , 1940 .

[45]  Irene Litvan,et al.  Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia , 2003, Annals of neurology.

[46]  A. Rajput,et al.  Progressive Supranuclear Palsy , 2001, Drugs & aging.

[47]  E. Tangalos,et al.  Neuropsychological tests' norms above age 55: COWAT, BNT, MAE token, WRAT-R reading, AMNART, STROOP, TMT, and JLO , 1996 .

[48]  E. Tangalos,et al.  Mayo's older americans normative studies: WAIS-R norms for ages 56 to 97 , 1992 .

[49]  James F. Malec,et al.  Mayo's older americans normative studies: Updated AVLT norms for ages 56 to 97 , 1992 .

[50]  M. Tinker A Visual Motor Gestalt Test and its Clinical Use. , 1940 .